fibrinogenpräparate

Fibrinogenpräparate refer to medicinal products containing fibrinogen, a protein essential for blood clotting. Fibrinogen is synthesized in the liver and plays a crucial role in the formation of a stable fibrin clot by converting to fibrin when activated by thrombin. These preparations are derived from human plasma or, in some cases, recombinant sources. They are administered intravenously to patients with fibrinogen deficiency or impaired fibrinogen function.

Indications for the use of fibrinogenpräparate include the treatment of acquired hypofibrinogenemia, which can occur due to massive bleeding, disseminated intravascular coagulation (DIC), or liver disease. Congenital fibrinogen disorders, such as afibrinogenemia and hypofibrinogenemia, are also treated with these products. The primary goal of administration is to restore adequate fibrinogen levels to achieve hemostasis and prevent or treat bleeding episodes.

The administration of fibrinogenpräparate is typically guided by laboratory measurements of plasma fibrinogen levels and the clinical assessment of bleeding. Dosage is individualized based on the patient's weight, the severity of the deficiency, and the clinical situation. Potential adverse effects are generally related to the administration of plasma-derived products, including the risk of transmitting viral infections, although screening and purification methods have significantly reduced this risk. Allergic reactions are also possible. Fibrinogenpräparate are an important therapeutic option in managing bleeding disorders related to fibrinogen deficiency.